Gulam H Bhimani, MD | |
70 Emory St, Attleboro, MA 02703-3142 | |
(508) 226-1693 | |
(508) 226-0167 |
Full Name | Gulam H Bhimani |
---|---|
Gender | Male |
Speciality | Urology |
Location | 70 Emory St, Attleboro, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073511994 | NPI | - | NPPES |
2061112 | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | 37846 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Gulam H Bhimani, MD 340 Main St, Ste 670, Worcester, MA 01608-1604 Ph: (508) 754-3566 | Gulam H Bhimani, MD 70 Emory St, Attleboro, MA 02703-3142 Ph: (508) 226-1693 |
News Archive
Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.
The Department of Health and Human Services has announced more than $19 million in grants to help 66 of the nation's health centers expand capacity to serve 270,000 more rural and inner-city Americans, including many without health insurance.
Varian Medical Systems has received regulatory clearance from the Indian Atomic Energy Regulatory Board for the use of its unique TrueBeam High Intensity Mode for advanced radiosurgical treatments.
Columbia University Medical Center (CUMC) scientists have developed a way to recreate an individual's immune system in a mouse. The "personalized immune mouse" offers researchers an unprecedented tool for individualized analysis of abnormalities that contribute to type 1 diabetes and other autoimmune diseases, starting at the onset of disease.
Value in Health, the official journal of ISPOR- the professional society for health economics and outcomes research, announced today the publication of new research from The Netherlands showing important gaps in the deployment of "coverage with evidence development," a type of pharmaceutical managed entry agreement that gives patients access to treatments while additional evidence is being collected.
› Verified 1 days ago